<SEC-DOCUMENT>0001157523-18-002470.txt : 20181126
<SEC-HEADER>0001157523-18-002470.hdr.sgml : 20181126
<ACCEPTANCE-DATETIME>20181126070016
ACCESSION NUMBER:		0001157523-18-002470
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20181126
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20181126
DATE AS OF CHANGE:		20181126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		181199944

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51904336.htm
<DESCRIPTION>TEVA PHARMACEUTICAL INDUSTRIES LIMITED 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2018 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-size: 16pt; font-family: Times New Roman"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font><br>
    </p>
    <p>

    </p>
    <hr style="color: #000000; width: 40%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-size: 16pt; font-family: Times New Roman"><b>FORM 8-K</b></font>
    </p>
    <hr style="color: #000000; width: 40%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>CURRENT
      REPORT</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Pursuant
      to Section 13 or 15(d)</b></font><b><font style="font-size: 12pt; font-family: Times New Roman"><br style="font-size: 12pt; font-family: Times New Roman"></font><font style="font-size: 12pt; font-family: Times New Roman">of
      the Securities Exchange Act of 1934</font></b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Date of
      Report (Date of earliest event reported) November 26, 2018</b></font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman"></font><br>
    </p>
    <hr style="color: #000000; width: 40%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-size: 20pt; font-family: Times New Roman"><b>TEVA&#160;PHARMACEUTICAL&#160;INDUSTRIES&#160;LIMITED</b></font><br><font style="font-size: 10pt; font-family: Times New Roman"><b>(Exact
      Name of registrant as specified in its charter)</b></font>
    </p>
    <hr style="color: #000000; width: 40%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <br>

    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Israel</b>
          </p>
        </td>
        <td style="white-space: nowrap; padding-right: 0.0px; padding-left: 0.0px; width: 34%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>001-16174</b>
          </p>
        </td>
        <td style="white-space: nowrap; padding-right: 0.0px; padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Not Applicable</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(State or other jurisdiction</b>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>of incorporation)</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 34%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(Commission</b>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>File Number)</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(IRS Employer</b>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Identification No.)</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>
      <b>5 Basel Street</b><br><b>P.O. Box 3190</b><br><b>Petach Tikva
      4951033, Israel</b><br><b>(Address of Principal Executive Offices,
      including Zip Code)</b><br><br><b>+972-3-914-8171</b><br><b>(Registrant&#8217;s
      Telephone Number, including Area Code)</b><br><br><b>Not Applicable</b><br><b>(Former
      Name or Former Address, if Changed Since Last Report)</b>
    </p>
    <hr style="height: 1.0 pt; width: 40%; color: #000000; text-align: center">


    <p style="text-align: center">

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions (see General Instruction A.2. below):</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <p>
      Indicate by check mark whether the registrant is an emerging growth
      company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
      of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
      (&#167;240.12b-2 of this chapter).
    </p>
    <p style="text-align: left">
      Emerging Growth Company&#160;&#160;<font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font>
    </p>
    <p>
      If an emerging growth company, indicate by check mark if the registrant
      has elected not to use the extended transition period for complying with
      any new or revised financial accounting standards provided pursuant to
      Section&#160;13(a) of the Exchange Act.&#160;&#160;<font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font>
    </p>
    <p>

    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <b>Item 7.01 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Regulation FD Disclosure.</b>
    </p>
    <p style="text-align: justify">
      On November&#160;26, 2018, Teva Pharmaceutical Industries Limited (the &#8220;<u>Company</u>&#8221;)
      provided notice to holders of its 7.00% Mandatory Convertible Preferred
      Shares (the &#8220;<u>Preferred Shares</u>&#8221;) that the Company will pay
      all of the accumulated and unpaid dividends on the Preferred Shares (the
      &#8220;<u>Mandatory Conversion Additional Conversion Amount</u>&#8221;) in
      American Depositary Shares (&#8220;<u>ADSs</u>&#8221;) of the Company.
    </p>
    <p style="text-align: justify">
      The Mandatory Conversion Date of the Preferred Shares is December 15,
      2018. On such date, each Preferred Share shall automatically convert
      (unless previously converted at the option of the holder thereof) into
      between 13.3333 and 16.0000 ADSs (the &#8220;<u>Mandatory Conversion Rate</u>&#8221;).
      In connection with such conversion, the Company will also pay the
      Mandatory Conversion Additional Conversion Amount in ADSs. Since the
      Mandatory Conversion Date is not a business day, the conversion will be
      processed by the transfer agent and conversion agent for the Preferred
      Shares on the next succeeding business day, December 17, 2018.
    </p>
    <p style="text-align: justify">
      The person or persons entitled to receive the ADSs issuable upon
      mandatory conversion of the Preferred Shares shall be treated as the
      record holder(s) of such ADSs as of 5:00 p.m., New York City time, on
      the Mandatory Conversion Date. The Company will pay cash in lieu of any
      fractional share upon conversion in accordance with the terms of the
      Company&#8217;s Articles of Association (the &#8220;<u>Articles</u>&#8221;).
    </p>
    <p style="text-align: justify">
      For purposes of calculating the Mandatory Conversion Additional
      Conversion Amount, the ADSs shall be valued at 97% of the average
      volume-weighted average price per ADS over the five consecutive Trading
      Day period beginning on and including the seventh scheduled trading day
      prior to the Mandatory Conversion Date (the &#8220;<u>Average Price</u>&#8221;).
      No fractional ADSs shall be delivered by the Company to holders of
      Preferred Shares in payment or partial payment of the Mandatory
      Conversion Additional Conversion Amount. The Company shall instead pay a
      cash adjustment to each holder of Preferred Shares that would otherwise
      be entitled to receive a fraction of an ADS based on the Average Price.
    </p>
    <p style="text-align: justify">
      The Company will withhold taxes at a rate of 20% on the Mandatory
      Conversion Additional Conversion Amount. Withholding taxes on the
      Mandatory Conversion Additional Conversion Amount will be calculated in
      the same manner as if the accumulated and unpaid dividends were paid in
      cash. The accumulated and unpaid dividends as of the Mandatory
      Conversion Date will be $259,875,000.
    </p>
    <p style="text-align: justify">
      Following the Mandatory Conversion Date, Preferred Shares will no longer
      be outstanding and all rights of the holders with respect to such
      Preferred Shares will terminate, except for the right to receive the
      number of whole ADSs issuable upon conversion of the Preferred Shares
      and cash in lieu of any fractional ADS, as described above.
    </p>
    <p style="text-align: justify">
      Upon the mandatory conversion of the Preferred Shares into ADSs, in
      accordance with the Articles, all Preferred Shares registered, but
      unissued, shall automatically be converted into ordinary shares on a
      one-for-one-basis, and the Articles shall be amended accordingly without
      any further act or approval.
    </p>
    <p style="text-align: justify">
      The foregoing description of the Preferred Shares does not purport to be
      complete and is qualified in its entirety by reference to the Articles
      of Association of the Company, which is filed as Exhibit 3.3 to the
      Company&#8217;s Form 10-K for the year ended December 31, 2017 and is
      incorporated herein by reference.
    </p>
    <p>

    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="width: 4%">

        </td>
        <td style="width: 46%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            TEVA PHARMACEUTICAL INDUSTRIES LTD.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 4%">

        </td>
        <td style="width: 46%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-bottom: 2.0px; padding-left: 0.0px; width: 4%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-bottom: 2.0px; padding-left: 0.0px; width: 46%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; border-bottom-style: solid; width: 5%; text-align: left" valign="top">
          By:
        </td>
        <td style="border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; border-bottom-style: solid; width: 45%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Michael McClellan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 4%">

        </td>
        <td style="width: 46%">

        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Name:
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 45%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Michael McClellan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 4%">

        </td>
        <td style="width: 46%">

        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Title:
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 45%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Executive Vice President and Chief
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 4%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Date:
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 46%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            November 26, 2018
          </p>
        </td>
        <td style="width: 5%">

        </td>
        <td style="padding-left: 0.0px; width: 45%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
